Oil prices dip on fears of slowing demand, oversupply
NEW YORK - Johnson & Johnson (NYSE:JNJ) announced Monday the appointment of John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors.
Morikis led Sherwin-Williams for eight years as CEO, overseeing the company’s expansion into 123 countries and its inclusion in the Dow Jones Industrial Average. He spent nearly four decades at the paint and coatings company after joining as a management trainee in 1984. This appointment comes as J&J’s stock trades near its 52-week high, with a current dividend yield of 2.92%.
"He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains," said Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson, in a press release statement.
During his tenure at Sherwin-Williams, Morikis spearheaded a company-wide transformation focused on talent development, innovation, and customer-driven solutions. He also guided supply chain optimization and technology investments to enhance operational efficiency.
Morikis currently serves on the boards of United Parcel Service, General Mills, and Whirlpool Corporation. He also serves as Chairman of the Board for University Hospitals Health System.
He holds bachelor’s degrees in Business Administration and Psychology from Saint Joseph’s College and a master’s degree in Business from National Louis University.
Johnson & Johnson, a global healthcare company, specializes in innovative medicine and medical technology development.
In other recent news, Johnson & Johnson reported strong financial results for the second quarter of 2025, with worldwide sales reaching $23.7 billion, reflecting a 4.6% operational sales growth. The company also increased its full-year sales guidance to $92.9 billion and raised its EPS guidance to $10.85. Additionally, Johnson & Johnson announced a significant $2 billion investment to expand its manufacturing presence in North Carolina. This development involves constructing a new 160,000+ square foot facility at FUJIFILM’s biopharmaceutical site in Holly Springs, aiming to create approximately 120 new jobs. In terms of analyst insights, Wolfe Research raised its price target for Johnson & Johnson to $195 from $175, maintaining an Outperform rating on the stock. The firm cited increased confidence in the company’s upcoming talc litigation outcome, resulting in lower weighted average cost of capital assumptions. These recent developments highlight Johnson & Johnson’s strategic efforts to strengthen its market position and operational capabilities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.